Oxford Nanopore Technologies plc Stock

Equities

ONT

GB00BP6S8Z30

Advanced Medical Equipment & Technology

Market Closed - London S.E. 11:35:29 2024-05-21 am EDT 5-day change 1st Jan Change
102.7 GBX -2.84% Intraday chart for Oxford Nanopore Technologies plc -7.64% -50.67%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 188M 239M Sales 2025 * 242M 307M Capitalization 912M 1.16B
Net income 2024 * -150M -191M Net income 2025 * -133M -169M EV / Sales 2024 * 3.37 x
Net cash position 2024 * 276M 351M Net cash position 2025 * 172M 218M EV / Sales 2025 * 3.06 x
P/E ratio 2024 *
-6.19 x
P/E ratio 2025 *
-7.13 x
Employees 1,238
Yield 2024 *
-
Yield 2025 *
-
Free-Float 70.12%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.31%
1 week-3.56%
Current month+7.47%
1 month+13.96%
3 months-24.23%
6 months-46.94%
Current year-49.23%
More quotes
1 week
105.70
Extreme 105.7
116.80
1 month
91.24
Extreme 91.243
116.80
Current year
91.24
Extreme 91.243
212.59
1 year
91.24
Extreme 91.243
279.00
3 years
91.24
Extreme 91.243
736.00
5 years
91.24
Extreme 91.243
736.00
10 years
91.24
Extreme 91.243
736.00
More quotes
Managers TitleAgeSince
Founder - 04-12-31
Director of Finance/CFO 42 Jan. 21
Chief Investment Officer - 18-12-31
Members of the board TitleAgeSince
Director/Board Member 66 21-06-23
Director/Board Member 58 Dec. 18
Chairman 59 22-07-31
More insiders
Date Price Change Volume
24-05-21 102.7 -2.84% 612 987
24-05-20 105.7 -2.31% 407,148
24-05-17 108.2 -2.96% 1,035,528
24-05-16 111.5 -1.76% 929,090
24-05-15 113.5 +2.07% 1,001,638

Delayed Quote London S.E., May 20, 2024 at 11:35 am EDT

More quotes
Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
1.057 GBP
Average target price
1.98 GBP
Spread / Average Target
+87.32%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW